The (11;14)(q13;q32) translocation in multiple myeloma - A morphologic and immunohistochemical study

被引:85
|
作者
Hoyer, JD
Hanson, CA
Fonseca, R
Greipp, PR
Dewald, GW
Kurtin, PJ
机构
[1] Mayo Clin, Dept Lab Med & Pathol, Rochester, MN 55905 USA
[2] Mayo Clin, Dept Internal Med, Div Hematol, Rochester, MN 55905 USA
关键词
t(11; 14)(q13; q32); multiple myeloma; cyclin D1; immunohistochemistry;
D O I
10.1309/4W8E-8F4K-BHUP-UBE7
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
We identified 24 cases of multiple myeloma with the t(11:14)(q13;q32). In 22 cases, the t(11;14)(q13;q32) was part of a complex karyotype, and in 2 cases it was an isolated abnormality. All patients had clinical and laboratory features consistent with multiple myeloma. The median degree of plasma cell involvement in the bone marrow was 60%, and in 10 cases, the plasma cells had a lymphoplasmacytoid appearance. Of the 24 cases, 21 had intermediate or high proliferative rates based on labeling index studies. Immunohistochemical studies performed on all bone marrow biopsy specimens showed strong cyclin D1 nuclear positivity in 19 cases. There also was strong cyclin D1 nuclear positivity found in 6 of 30 additional cases without the t(11;14)(q13;q32) demonstrated by routine cytogenetics. The t(11;14)(q13;q32) in multiple myeloma results in over-expression of the cyclin D1 protein, which can be demonstrated by immunohistochemical stain. The cyclin D1 stain results in the additional cases of multiple myeloma suggest that the t(11;14)(q13;q32) may be more common than previously thought and may be missed by routine cytogenetics, particularly if the proliferative rate is low.
引用
收藏
页码:831 / 837
页数:7
相关论文
共 50 条
  • [41] The CCND1 c.870G>A polymorphism is a risk factor for t(11;14)(q13;q32) multiple myeloma
    Niels Weinhold
    David C Johnson
    Daniel Chubb
    Bowang Chen
    Asta Försti
    Fay J Hosking
    Peter Broderick
    Yussanne P Ma
    Sara E Dobbins
    Dirk Hose
    Brian A Walker
    Faith E Davies
    Martin F Kaiser
    Ni L Li
    Walter A Gregory
    Graham H Jackson
    Mathias Witzens-Harig
    Kai Neben
    Per Hoffmann
    Markus M Nöthen
    Thomas W Mühleisen
    Lewin Eisele
    Fiona M Ross
    Anna Jauch
    Hartmut Goldschmidt
    Richard S Houlston
    Gareth J Morgan
    Kari Hemminki
    Nature Genetics, 2013, 45 : 522 - 525
  • [42] The ultrastructure of mantle cell lymphoma and other B-cell disorders with translocation t(11;14)(q13;q32)
    Resnitzky, P
    Matutes, E
    Hedges, M
    Morilla, R
    BritoBabapulle, V
    Khokhar, T
    Catovsky, D
    BRITISH JOURNAL OF HAEMATOLOGY, 1996, 94 (02) : 352 - 361
  • [43] Clinicopathologic Analysis of the Impact of CD23 Expression in Plasma Cell Myeloma with t(11;14)(q13;q32)
    Buonaccorsi, J. N.
    Kroft, S. H.
    Harrington, A.
    Van Tuinen, P.
    Olteanu, H.
    LABORATORY INVESTIGATION, 2011, 91 : 288A - 288A
  • [44] Clinicopathologic Analysis of the Impact of CD23 Expression in Plasma Cell Myeloma with t(11;14)(q13;q32).
    Buonaccorsi, J. N.
    Kroft, S. H.
    Harrington, A.
    VanTuinen, P.
    Olteanu, H.
    MODERN PATHOLOGY, 2011, 24 : 288A - 288A
  • [45] Clinicopathologic analysis of the impact of CD23 expression in plasma cell myeloma with t(11;14)(q13;q32)
    Buonaccorsi, J. Noelle
    Kroft, Steven H.
    Harrington, Alexandra M.
    VanTuinen, Peter
    Olteanu, Horatiu
    ANNALS OF DIAGNOSTIC PATHOLOGY, 2011, 15 (06) : 385 - 388
  • [46] The CCND1 c.870G>A polymorphism is a risk factor for t(11;14)(q13;q32) multiple myeloma
    Weinhold, Niels
    Johnson, David C.
    Chubb, Daniel
    Chen, Bowang
    Foersti, Asta
    Hosking, Fay J.
    Broderick, Peter
    Ma, Yussanne P.
    Dobbins, Sara E.
    Hose, Dirk
    Walker, Brian A.
    Davies, Faith E.
    Kaiser, Martin F.
    Li, Ni L.
    Gregory, Walter A.
    Jackson, Graham H.
    Witzens-Harig, Mathias
    Neben, Kai
    Hoffmann, Per
    Noethen, Markus M.
    Muehleisen, Thomas W.
    Eisele, Lewin
    Ross, Fiona M.
    Jauch, Anna
    Goldschmidt, Hartmut
    Houlston, Richard S.
    Morgan, Gareth J.
    Hemminki, Kari
    NATURE GENETICS, 2013, 45 (05) : 522 - U87
  • [47] Prevalence of the t(11; 14)(q13; q32) immunoglobulin H/CCND1 in Mexican mestizos with multiple myeloma: A single institution experience
    Lira-Lara, Olivia
    Gallardo-Perez, Moises Manuel
    Garces-Eisele, Solon Javier
    Reyes-Nunez, Virginia Adriana
    Lopez-Trujillo, Miguel Antonio
    Melgar-de-la-Paz, Miranda
    Negrete-Rodriguez, Paola
    Hamilton-Aviles, Luis Enrique
    Ocana-Ramm, Guillermo
    Robles-Nasta, Max
    Sanchez-Bonilla, Daniela
    Olivares-Gazca, Juan Carlos
    Ruiz-Delgado, Guillermo Jose
    Ruiz-Arguelles, Guillermo Jose
    IRAQI JOURNAL OF HEMATOLOGY, 2024, 13 (01) : 150 - 153
  • [48] Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and-17p13 in myeloma patients treated with high-dose therapy
    Gertz, MA
    Lacy, MQ
    Dispenzieri, A
    Greipp, PR
    Litzow, MR
    Henderson, KJ
    Van Wier, SA
    Ahmann, GJ
    Fonseca, R
    BLOOD, 2005, 106 (08) : 2837 - 2840
  • [49] Translocation t(14;16)(q32;q23) in patients with multiple myeloma (MM)
    Pavlistova, L.
    Berkova, A.
    Svobodova, K.
    Izakova, S.
    Spicka, I.
    Straub, J.
    Michalova, K.
    Zemanova, Z.
    EUROPEAN JOURNAL OF HUMAN GENETICS, 2020, 28 (SUPPL 1) : 558 - 559
  • [50] Immunophenotypic and laboratory features of t(11;14)(q13;q32)-positive plasma cell neoplasms
    Shi, Min
    Ternus, Jessica A.
    Ketterling, Rhett P.
    Jevremovic, Dragan
    McPhail, Ellen D.
    LEUKEMIA & LYMPHOMA, 2018, 59 (08) : 1913 - 1919